# A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma

> **NCT07691476** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yonsei University** · enrollment: 48 (estimated)

## Conditions studied

- Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Zanzalintinib and Pembrolizumab

## Key facts

- **NCT ID:** NCT07691476
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2028-10-31
- **Final completion:** 2029-02-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691476, "A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*